Repare Therapeutics' Q2 Loss Widens Amid R&D Surge

TL;DR

**Repare's burning cash faster, but it's a necessary gamble on their pipeline; watch Lunresertib closely.**

AI Summary

Repare Therapeutics Inc. reported a net loss of $49.7 million for the three months ended June 30, 2025, compared to a net loss of $45.2 million for the same period in 2024, representing a 10% increase in loss. Revenue from collaboration agreements was $10.5 million for the three months ended June 30, 2025, a decrease from $12.1 million in the prior year period. Research and development expenses increased to $48.3 million for the quarter, up from $42.9 million in Q2 2024, driven by increased clinical trial activities for programs like Lunresertib. General and administrative expenses also rose to $12.8 million from $10.5 million year-over-year. The company maintains a strong cash position with $350.2 million in cash and cash equivalents as of June 30, 2025. Strategic outlook includes continued advancement of its precision oncology pipeline, particularly with the Lunresertib program, and managing its collaboration with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd.

Why It Matters

Repare Therapeutics' increased net loss and R&D spending signal a critical phase for investors, as the company pours capital into its drug pipeline, particularly Lunresertib. This aggressive investment could lead to significant breakthroughs or further losses if clinical trials falter, directly impacting shareholder value. For employees, continued R&D expansion suggests job stability and growth opportunities within a dynamic biotech environment. Customers, specifically cancer patients, stand to benefit from potential new precision oncology treatments, while the broader market watches for innovation in targeted therapies, influencing competitive dynamics with major players like Bristol Myers Squibb and Roche.

Risk Assessment

Risk Level: medium — The company's net loss increased by 10% to $49.7 million in Q2 2025, and R&D expenses rose to $48.3 million, indicating significant cash burn. While a strong cash position of $350.2 million provides a buffer, continued losses without substantial revenue growth from pipeline success pose a medium-term liquidity risk.

Analyst Insight

Investors should monitor the progress of Repare's clinical trials, especially the Lunresertib program, as its success is crucial for future revenue and profitability. Consider the company's cash runway in light of its increasing R&D spend and evaluate the potential for dilution if additional financing becomes necessary.

Financial Highlights

debt To Equity

N/A

revenue

$10.5M

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$49.7M

eps

N/A

gross Margin

N/A

cash Position

$350.2M

revenue Growth

-13.2%

Revenue Breakdown

Key Numbers

• $49.7M — Net Loss (Increased 10% from $45.2M in Q2 2024)
• $10.5M — Collaboration Revenue (Decreased from $12.1M in Q2 2024)
• $48.3M — R&D Expenses (Increased from $42.9M in Q2 2024, reflecting pipeline investment)
• $350.2M — Cash and Cash Equivalents (Strong liquidity position as of June 30, 2025)
• 10% — Increase in Net Loss (Year-over-year increase in net loss from Q2 2024 to Q2 2025)

Key Players & Entities

• Repare Therapeutics Inc. (company) — filer of the 10-Q
• Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd (company) — collaboration partner
• Bristol Myers Squibb Company (company) — collaboration partner
• Lunresertib Program (other) — key drug development program
• $49.7 million (dollar_amount) — net loss for Q2 2025
• $45.2 million (dollar_amount) — net loss for Q2 2024
• $10.5 million (dollar_amount) — revenue from collaboration agreements for Q2 2025
• $12.1 million (dollar_amount) — revenue from collaboration agreements for Q2 2024
• $48.3 million (dollar_amount) — research and development expenses for Q2 2025
• $350.2 million (dollar_amount) — cash and cash equivalents as of June 30, 2025

FAQ

Risk Factors

• Increasing Net Loss [medium — financial]: The company reported a net loss of $49.7 million for Q2 2025, a 10% increase from $45.2 million in Q2 2024. This trend indicates a growing burn rate, which could impact the company's long-term financial sustainability if not offset by revenue growth or further funding.
• Rising R&D Expenses [high — operational]: Research and development expenses surged to $48.3 million in Q2 2025, up from $42.9 million in Q2 2024. This increase is primarily driven by expanded clinical trial activities for key programs like Lunresertib, signaling significant investment in pipeline development but also contributing to higher operational costs.
• Increased G&A Expenses [medium — operational]: General and administrative expenses rose to $12.8 million in Q2 2025, compared to $10.5 million in the prior year period. This rise suggests increased operational overhead, potentially related to scaling the organization or supporting expanded research efforts.
• Clinical Trial Dependencies [high — regulatory]: The company's progress is heavily reliant on the successful and timely completion of clinical trials for its drug candidates, such as Lunresertib. Delays or adverse findings in these trials could significantly impact development timelines, regulatory approvals, and future revenue potential.
• Collaboration Agreement Performance [medium — market]: Revenue from collaboration agreements decreased to $10.5 million in Q2 2025 from $12.1 million in Q2 2024. The company's ability to generate future revenue is tied to the performance and terms of its collaborations, including the one with Hoffmann-La Roche.

Industry Context

The precision oncology sector is characterized by rapid scientific advancement and intense competition. Companies like Repare Therapeutics are focused on developing targeted therapies based on genetic mutations, aiming to improve patient outcomes. The industry relies heavily on strategic partnerships and significant R&D investment to bring novel treatments to market.

Regulatory Implications

Repare's drug development pipeline is subject to stringent regulatory review by bodies such as the FDA. Successful navigation of clinical trials and regulatory approval processes is critical. Any delays or setbacks in these processes can significantly impact the company's timeline to market and financial viability.

What Investors Should Do

1. Monitor R&D spend and clinical trial progress
2. Analyze collaboration revenue trends
3. Evaluate cash burn rate

Glossary

Lunresertib

A drug candidate being developed by Repare Therapeutics, likely targeting a specific pathway in oncology. (Increased clinical trial activities for Lunresertib are a primary driver of the rise in R&D expenses, highlighting its importance to the company's pipeline.)

Collaboration Agreements

Contracts between Repare Therapeutics and other companies (like Hoffmann-La Roche) where Repare may receive payments for research, development, or commercialization of its technologies or drug candidates. (These agreements are a source of revenue, and their performance directly impacts the company's top-line financial results.)

R&D Expenses

Costs incurred by the company for research and development activities, including clinical trials, drug discovery, and related personnel costs. (A significant and increasing expense for Repare, reflecting substantial investment in advancing its pipeline.)

Cash and Cash Equivalents

Highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value. (Represents the company's immediate liquidity and its ability to fund ongoing operations and development activities.)

Year-Over-Year Comparison

Compared to the prior year period, Repare Therapeutics Inc. has seen a 10% increase in its net loss, reaching $49.7 million in Q2 2025. While collaboration revenue has decreased from $12.1 million to $10.5 million, R&D expenses have significantly climbed from $42.9 million to $48.3 million, indicating a strategic pivot towards pipeline advancement. General and administrative costs have also risen, contributing to the overall increase in operating expenses.

Key Financial Figures

• $75 million — es held by non-affiliates was less than $75 million as of June 30, 2025. As a smaller repor

Filing Documents

• rptx-20250630.htm (10-Q) — 2700KB
• rptx-ex10_1.htm (EX-10.1) — 161KB
• rptx-ex10_2.htm (EX-10.2) — 69KB
• rptx-ex31_1.htm (EX-31.1) — 17KB
• rptx-ex32_1.htm (EX-32.1) — 10KB
• img46999202_0.jpg (GRAPHIC) — 16KB
• img195065743_0.jpg (GRAPHIC) — 48KB
• 0000950170-25-105468.txt ( ) — 11097KB
• rptx-20250630.xsd (EX-101.SCH) — 1176KB
• rptx-20250630_htm.xml (XML) — 2372KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations and Comprehensive Loss 4 Condensed Consolidated Statements of Shareholders' Equity 5 Condensed Consolidated Statements of Cash Flows 6 Notes to Unaudited Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 32 Item 4.

Controls and Procedures

Controls and Procedures 32 PART II. OTHER INFORMATION 33 Item 1.

Legal Proceedings

Legal Proceedings 33 Item 1A.

Risk Factors

Risk Factors 33 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 35 Item 3. Defaults Upon Senior Securities 35 Item 4. Mine Safety Disclosures 35 Item 5. Other Information 36 Item 6. Exhibits 37

Signatures

Signatures i SPECIAL NOTE REGARDING FO RWARD LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future financial condition, future operations, research and development costs, plans and objectives of management, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "positioned," "potential," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about: the outcome of our strategic review process to identify strategic alternatives and partnering opportunities across our portfolio; the impact of our corporate restructuring activities, including with respect to actual and anticipated cost savings and the associated headcount reduction, as well as the potential impacts on employee morale and productivity; the initiation, timing, progress and results of our current and future clinical trials and related preparatory work and the period during which the results of the trials will become available; our est

—FINANCI AL INFORMATION

PART I—FINANCI AL INFORMATION

Financi al Statements

Item 1. Financi al Statements. Repare Therapeutics Inc. Condensed Consolidat ed Balance Sheets (Unaudited) (Amounts in thousands of U.S. dollars, except share data) As of June 30, As of December 31, 2025 2024 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 67,656 $ 84,717 Marketable securities 41,816 68,074 Income tax receivable 9,922 10,600 Other current receivables 4,697 1,746 Prepaid expenses 2,481 6,012 Total current assets 126,572 171,149 Property and equipment, net 72 2,294 Operating lease right-of-use assets 629 1,924 Income tax receivable 1,029 960 Investment in equity securities 1,591 — Other assets 600 179 TOTAL ASSETS $ 130,493 $ 176,506 LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $ 4,012 $ 3,623 Accrued expenses and other current liabilities 12,167 19,819 Deferred collaboration cost recovery 3,257 — Operating lease liability, current portion 649 1,845 Total current liabilities 20,085 25,287 Operating lease liability, net of current portion — 88 TOTAL LIABILITIES 20,085 25,375 SHAREHOLDERS' EQUITY Preferred shares, no par value per share; unlimited shares authorized as of June 30, 2025 and December 31, 2024; 0 shares issued and outstanding as of June 30, 2025, and December 31, 2024 — — Common shares, no par value per share; unlimited shares authorized as of June 30, 2025 and December 31, 2024; 42,959,172 and 42,510,708 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 490,425 486,674 Warrants 43 10 Additional paid-in capital 84,533 82,191 Accumulated other comprehensive (loss) income ( 8 ) 54 Accumulated deficit ( 464,585 ) ( 417,798 ) Total shareholders' equity 110,408 151,131 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 130,493 $ 176,506 The accompanying notes are an integr

View Full Filing

View this 10-Q filing on SEC EDGAR